Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

Human Gene Therapy

Volumn 17, Issue 2, 2006, Pages 239-244

  Kaufman, Howard L ^a,c   Cohen, Seth ^a   Cheung, Ken ^a   DeRaffele, Gail ^a   Mitcham, Josephine ^a   Moroziewicz, Dorota ^a   Schlom, Jeffrey ^b   Hesdorffer, Charles ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VACCINIA ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DYSPNEA; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GENE DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INJECTION SITE REACTION; MALE; MELANOMA; MICROENVIRONMENT; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; PAIN; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL; PRURITUS; RASH; TUMOR CELL; VACCINATION; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS EXPRESSION; VITILIGO; VOMITING;

ADULT; AGED; ANTIGENS, CD80; FEMALE; GENETIC VECTORS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES; TREATMENT FAILURE; VACCINES, SYNTHETIC; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 33144480152     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.239     Document Type: Article

References (22)

1. CHEN, H., and HENDRICKS, R.L. (1998). B7 costimulatory requirements of T cells at an inflammatory site. J. Immunol. 160, 5045-5052.
2. CHEN, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336-347.
3. CHIRATHAWORN, C., KOHLMEIER, J.E., TIBBETTS, S.A., RUMSEY, L.M., CHAN, M.A., and BENEDICT, S.H. (2002). Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J. Immunol. 168, 5530-5537.
4. DUNUSSI-JOANNOPOULOS, K., WEINSTEIN, H.J., NICKERSON, P.W., STROM, T.B., BURAKOFF, S.J., CROOP, J.M., and ARCECI, R.J. (1996). Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87, 2938-2946.
5. +-mediated rejection of established tumors. Hum. Gene Ther. 8, 477-848.
6. GROSENBACH, D., BARRIENTOS, J., SCHLOM, J., and HODGE, J. (2001). Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61, 4497-4505.
7. HAVARI, E., LENNON-DUMENIL, A.M., KLEIN, L., NEELY, D., TAYLOR, J.A., McINERNEY, M.F., WUCHERPFENNIG, W.K., and LIPES, M.A. (2004). Expression of the B7.1 costimulatory molecule on pancreatic beta cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J. Immunol. 173, 787-796.
8. HENNING, T., KRAUS, M., BRISCHWEIN, M., OTTO, A., and WOLF, B. (2004). Relevance of tumor microenvironment for progression, therapy, and drug development. Anticancer Drugs 15, 7-14.
9. HODGE, J.W., RAD, A.N., GROSENBACH, D.W., SABZEVARI, H., YAFAL, A.G., GRITZ, L., and SCHLOM, I. (2000). Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl. Cancer Inst. 92, 1228-1239.
10. HODGE, J.W., GROSENBACH, D., AARTS, W., POOLE, D., and SCHLOM, J. (2003). Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9, 1837-1849.
11. HODGE, J.W., CHAKRABORTY, M., KUDO-SAITO, C., GARNETT, C.T., and SCHLOM, J. (2005). Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174, 5994-6004.
12. KALUS, R., KANTOR, J., GRITZ, L., A, G.Y., MAZZARA, G., SCHLOM, J., and HODGE, J. (1999). The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 17, 893-903.
13. KAUFMAN, H.L., DERAFFELE, G., DIVITO, J., HORIG, H., LEE, D., PANICALI, D., and VOULO, M. (2001). A phase I trial of intralesional rV-TRICOM vaccine in the treatment of malignant melanoma. Hum. Gene Ther. 12, 1459-1480.
14. KAUFMAN, H.L., DERAFFELE, G., MITCHAM, I., MOROZIEWICZ, D., COHEN, S.M., HURST-WICKER, K.S., CHEUNG, K., LEE, D.S., DIVITO, I., VOULO, M., DONOVAN, I., DOLAN, K., MANSON, K., PANICALI, D., WANG, E., HORIG, H., and MARINCOLA, F.M. (2005). Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J. Clin. Invest. 115, 1903-1912.
15. KUDO-SAITO, C., SCHLOM, J., and HODGE, J.W. (2005). Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin. Cancer Res. 11, 2416-2426.
16. OCHSENBEIN, A., SIERRO, S., ODERMATT, B., PERICIN, M., KARRER, U., HERMANS, J., HEMMI, S., HENGARTNER, H., and ZINKERNAGEL, R. (2001). Roles of tumour localization, second signals, and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
17. + T cells. J. Immunol. 158, 637-642.
18. + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy. Cancer Gene Ther. 11, 665-680.
19. TSUJI, H., KAWAGUCHI, S., WADA, T., NAGOYA, S., INOBE, M., YAMASHITA, T., ISHII, S., and UEDE, T. (2002), Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 9, 747-755.
20. VAN KEMPEN, L., RUITER, D, VAN MUIJEN, G., and COUSSENS, L. (2003). The tumor microenvironment: A critical determinant of neoplastic evolution. Eur. J. Cell Biol. 82, 539-548.
21. ZHU, M., TERASAWA, H., GULLEY, J., PANICALI, D., ARLEN, P., SCHLOM, J., and TSANG, K.Y. (2001). Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61, 3725-3734.
22. ZIPPELIUS, A., BATARD, P., RUBIO-GODOY, V., BIOLEY, G., LIENARD, D., LEJEUNE, F., RIMOLDI, D., GUILLAUME, P., MEIDENBAUER, N., MACKENSEN, A., RUFER, N., LUBENOW, N., SPEISER, D., CEROTTINI, J.C., ROMERO, P., and PITTET, M.J. (2003). Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res. 63, 2535-2545.